{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:31:32Z","timestamp":1783488692021,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ejca.2024.113539","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T01:55:31Z","timestamp":1705802131000},"page":"113539","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial"],"prefix":"10.1016","volume":"199","author":[{"given":"Panpan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongmei","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heli","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desheng","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunjiao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolei","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiguo","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panfeng","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2024.113539_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.ejca.2024.113539_bib2","unstructured":"NCCN Guidelines Version 2. 2022 Neuroendocrine and adrenal tumors. Available from: \u3008https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/neuroendocrine.pdf\u3009. (accessed."},{"issue":"7","key":"10.1016\/j.ejca.2024.113539_bib3","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113539_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1530\/ERC-15-0075","article-title":"Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma","volume":"22","author":"Hadoux","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2024.113539_bib5","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1530\/ERC-12-0002","article-title":"FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3","volume":"19","author":"Hentic","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"18","key":"10.1016\/j.ejca.2024.113539_bib6","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2024.113539_bib7","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3390\/biom12081031","article-title":"Dostarlimab: a review","volume":"12","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.ejca.2024.113539_bib8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"1-2","key":"10.1016\/j.ejca.2024.113539_bib9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1615\/ForumImmunDisTher.2015014188","article-title":"Reinvigorating exhausted T cells by blockade of the PD-1 pathway","volume":"6","author":"Lee","year":"2015","journal-title":"Immunopathol Dis Ther"},{"issue":"2","key":"10.1016\/j.ejca.2024.113539_bib10","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2024.113539_bib11","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221096219","article-title":"Immune escape mechanisms and therapeutic approaches in cancer: the cancer-immunity cycle","volume":"14","author":"Starzer","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.ejca.2024.113539_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108211","article-title":"The roles of TGF-beta and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.","volume":"240","author":"Bu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ejca.2024.113539_bib13","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211042689","article-title":"Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs)","volume":"13","author":"Xu","year":"2021","journal-title":"Ther Adv Med Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2024.113539_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1080\/14737140.2021.1944110","article-title":"Surufatinib for the treatment of advanced extrapancreatic neuroendocrine tumors","volume":"21","author":"Lu","year":"2021","journal-title":"Expert Rev Anticancer Ther"},{"issue":"11","key":"10.1016\/j.ejca.2024.113539_bib15","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2024.113539_bib16","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2024.113539_bib17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00432-021-03898-8","article-title":"Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial","volume":"149","author":"Cao","year":"2022","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113539_bib18","article-title":"Toripalimab: the first domestic anti-tumor PD-1 antibody in China","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ejca.2024.113539_bib19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2024.113539_bib20","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1158\/1078-0432.CCR-13-0895","article-title":"Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements","volume":"19","author":"Nishino","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.113539_bib21","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0. Available from: \u3008https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5\u00d77.pdf\u3009. (accessed."},{"issue":"3","key":"10.1016\/j.ejca.2024.113539_bib22","doi-asserted-by":"crossref","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","article-title":"Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer","volume":"143","author":"Kulangara","year":"2019","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejca.2024.113539_bib23","unstructured":"Roche Diagnostics GmbH. VENTANA PD-L1 (SP263) assay staining of non-small cell lung cancer. Interpretation guide. Available from: \u3008https:\/\/www.rochebiomarkers.be\/content\/media\/Files\/PD-L1_SP263_interpretation_guide_NSCLC.pdf\u3009. (accessed."},{"issue":"6","key":"10.1016\/j.ejca.2024.113539_bib24","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1001\/jamaoncol.2022.0212","article-title":"Assessment of clinical response following atezolizumab and bevacizumab treatment in patients with neuroendocrine tumors: a nonrandomized clinical trial","volume":"8","author":"Halperin","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.113539_bib25","doi-asserted-by":"crossref","unstructured":"Capdevila J., Teule A., L\u00f3pez C., Garc\u00eda-Carbonero R., Benavent M., Custodio A., et al. A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601). Presented at: ESMO S770-S771.","DOI":"10.1016\/j.annonc.2020.08.1370"},{"key":"10.1016\/j.ejca.2024.113539_bib26","unstructured":"Min Cheng S.F., Renxiang Tang, Wei Zhang, Jia Hu, Pan Wang, Juntao Yu, Cong Wang, Linfang Wang, Weiguo Qing, Yongxin Ren, and Weiguo Su. Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint blockade or chemotherapy in preclinical tumor models. Presented at: EORTC;"},{"issue":"40","key":"10.1016\/j.ejca.2024.113539_bib27","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1200\/JCO.2022.40.16_suppl.4125","article-title":"REGOMUNE: Phase II study of regorafenib plus avelumab in solid tumors\u2014results of the gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) cohort","author":"Sophie Cousin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113539_bib28","unstructured":"Taymeyah Al-Toubah B.M., Mintallah Haider, Tiffany Valone, and Jonathan Strosberg. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. Presented at: NANETS;"},{"issue":"10","key":"10.1016\/j.ejca.2024.113539_bib29","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1158\/1078-0432.CCR-19-4000","article-title":"Efficacy, safety, and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial","volume":"26","author":"Lu","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.113539_bib30","doi-asserted-by":"crossref","unstructured":"Girard N., Mazieres J., Otto J., Lena H., Lepage C., Egenod T., et al. Nivolumab (nivo) \u00b1 ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC). Presented at: ESMO; S1318.","DOI":"10.1016\/j.annonc.2021.08.2119"},{"issue":"1","key":"10.1016\/j.ejca.2024.113539_bib31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000487237","article-title":"Clinical and biomarker evaluations of sunitinib in patients with grade 3 digestive neuroendocrine neoplasms","volume":"107","author":"Pellat","year":"2018","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.ejca.2024.113539_bib32","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.ejca.2017.04.009","article-title":"Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: are they really heterogeneous? Insights from the FFCD-GTE national cohort","volume":"79","author":"Walter","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113539_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102015","article-title":"NET-02: a randomised, non-comparative, phase II trial of nal-IRI\/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"60","author":"McNamara","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"3","key":"10.1016\/j.ejca.2024.113539_bib34","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1470-2045(23)00001-3","article-title":"Bevacizumab plus FOLFIRI after failure of platinum-etoposide first-line chemotherapy in patients with advanced neuroendocrine carcinoma (PRODIGE 41-BEVANEC): a randomised, multicentre, non-comparative, open-label, phase 2 trial","volume":"24","author":"Walter","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2024.113539_bib35","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13249","article-title":"European neuroendocrine tumor society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma","volume":"35","author":"Sorbye","year":"2023","journal-title":"J Neuroendocr"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:41:43Z","timestamp":1760733703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":35,"alternative-id":["S0959804924000157"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113539","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113539","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113539"}}